Retatrutide 4 mg is an investigational metabolic peptide attracting significant attention in obesity and weight‑management research. Unlike earlier therapies, Retatrutide acts as a triple receptor agonist, targeting GLP‑1, GIP, and glucagon receptors simultaneously. This multi‑pathway approach is designed to influence appetite regulation, glucose control, energy expenditure, and fat m... https://blogs.bgsu.edu/artc413drings/concept-art/background-2/comment-page-375/#comment-20390